Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chuo Ku
Clinical trial register · Japan

Clinical Trials in Chuo Ku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie24 Novartis Pharmaceuticals15 Pfizer15 Eli Lilly and Company9 Amgen8
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Chuo Ku

147 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
National Cancer Center, Japan
Phase 2
35
Yokohama, Chuo-ku
2027-02-01
Not yet open
Pfizer
Phase 3
920
Chuo-ku
2026-09-28
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
392
Chuo-ku, Koto-ku
2026-09-02
Recruiting
Pfizer
Phase 3
1,375
Nagoya, Kagoshima, Yokohama, Sakai, Saitama, Chuo-ku, Tachikawa, Toshima-ku
2026-08-24
Recruiting
AbbVie
Phase 2
168
Yokohama, Osaka, Chuo-Ku
2026-08-17
Recruiting
Genmab
Phase 1
112
Hirakata, Chuo Ku, Koto-Ku
2026-08-13
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsASP2138·Folinic acid·Adrucil·Capecitabine
Astellas Pharma Global Development, Inc.
Phase 3
570
Chuo-ku, Niigata
2026-07-28
Recruiting
Bristol-Myers Squibb
Phase 2
260
Chuo-ku
2026-07-27
Recruiting
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
NCT07617337ALK Positive Non-small Cell Lung Cancer
DrugLorlatinib
Chugai Pharmaceutical
Phase 1
102
Nagoya, Kashiwa, Sakai, Nagaizumi-cho, Chuo-ku, Koto-Ku
2026-07-24
Recruiting
Amgen
Phase 3
3,200
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2026-07-23
Recruiting
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
NCT07630961Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
66
Chuo Ku
2026-06-23
Recruiting
Pfizer
Phase 3
954
Suita, Chuo-ku, Shinjuku-ku
2026-06-10
Recruiting
Novartis Pharmaceuticals
Phase 2
323
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2026-05-07
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Kashiwa-shi, Chuo-ku, Koto-ku
2026-05-04
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Chuo Ku
2026-04-14
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Nagoya, Kashiwa-shi, Chuo-ku, Koto-ku
2026-04-08
Recruiting
Takeda
Phase 3
1,182
Minami-ku, Nagoya-shi, Nagoya, Fukuoka, Tsu, Mie, Sasebo-shi, Osaka, Chuo-ku, Meguro-Ku
2026-03-11
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Kashiwa-shi, Hirakata-shi, Chuo-ku, Koto-ku
2026-02-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
240
Hirakata, Chuo-ku
2026-02-03
Recruiting
TheraSphere Japan Pre-Market Study
NCT07377487Liver Neoplasms
Boston Scientific Corporation
Not applicable
51
Nishinomiya, Kanazawa, Kashihara, Sayama, Chuo Ku
2026-01-22
Recruiting
AbbVie
Phase 2/3
490
Sapporo, Sagamihara-shi, Chuo-Ku, Wakayama
2025-12-10
Recruiting
Pfizer
Phase 1/2
138
Nagoya, Kashiwa, Sakai, Chuo-ku, Fukuoka
2025-12-01
Recruiting
AbbVie
Phase 2
100
Nagoya, Kashiwa-shi, Fukuoka, Sapporo, Kyoto, Sendai, Okayama, Chuo-Ku
2025-12-01
Recruiting
AbbVie
Phase 2
180
Kashiwa-shi, Sunto-gun, Bunkyo Ku, Chuo-Ku, Wakayama
2025-11-25
Recruiting
Pfizer
Phase 2
165
Takasaki, Kawasaki-shi, Yokohama, Sakai, Chuo-ku
2025-11-20
Active, closed
Bayer
Phase 2
60
Nagoya, Kobe, Chuo-Ku, Osaka
2025-11-19
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Nagoya, Kashiwa, Sapporo, Yokohama, Chuo-ku, Koto, Osaka
2025-10-23
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Chuo Ku
2025-10-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
540
Chuo-ku
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1
32
Yokohama, Sunto-gun, Chuo-ku, Koto-ku
2025-10-15
Recruiting
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Active, closed
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 2
20
Nagoya, Chuo Ku, Osaka
2025-08-08
Recruiting
AbbVie
Phase 2/3
854
Yokohama, Niigata, Takatsuki, Sunto-gun, Bunkyo-ku, Chuo-Ku
2025-08-03
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Kashiwa, Hirakata, Chuo-ku, Koto-ku
2025-08-01
Recruiting
Amgen
Phase 1
434
Nagoya, Kashiwa-shi, Chuo-ku
2025-07-31
Recruiting
AbbVie
Phase 2
377
Akashi-shi, Chuo-Ku, Koto-ku
2025-07-30
Recruiting
Celgene
Phase 3
400
Nagoya, Sapporo, Himeji, Morioka, Chuo-ku, Itabashiku, Chūō, Fukuoka
2025-07-28
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba
2025-07-01
Active, closed
Pfizer
Phase 1/2
74
Nagoya, Yokohama, Suita, Chuo-ku, Koto
2025-06-30
Recruiting
Chugai Pharmaceutical
Phase 1
130
Kashiwa, Chuo-ku
2025-06-05
Recruiting
Pfizer
Phase 2
252
Aki-gun Fuchu-cho, Kobe, Kawachi-Nagano, Sakai, Fujieda, Hamamatsu, Chuo-ku, Hachiōji
2025-05-20
Recruiting
AbbVie
Phase 2
390
Nagoya, Kashiwa-shi, Kawasaki-shi, Sendai, Chuo-Ku
2025-04-24
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
Tanabe Pharma America, Inc.
Phase 1/2
27
Chuo-Ku, City
2025-04-18
Recruiting
AbbVie
Phase 1
232
Kashiwa-shi, Hirakata-shi, Chuo-Ku
2025-04-14
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Chuo Ku
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2025-03-26
Recruiting
Bayer
Phase 1/2
450
Nagoya, Kashiwa, Sakai, Sunto, Chuo-ku, Koto-ku
2025-03-21
Active, closed
Amgen
Phase 3
3,853
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2025-03-12
Recruiting
AbbVie
Phase 1/2
252
Nagoya, Hirosaki, Yokohama, Kyoto, Niigata, Takatsuki, Chuo-Ku, Koto-ku
2025-03-06
Not yet open
National Cancer Center, Japan
Observational
350
Chuo-ku
2025-03-01
Recruiting
Takeda
Phase 3
171
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-02-27
Recruiting
Bayer
Phase 2
111
Nagoya, Kashiwa, Sapporo, Sakai, Chuo-ku, Koto-ku
2025-02-13
Active, closed
Amgen
Phase 2
61
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2024-12-26
Active, closed
AbbVie
Phase 2
185
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-Ku, Koto-ku
2024-12-13
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
23
Nagoya, Sapporo, Kobe, Osaka, Chuo-ku, Chiba, Fukuoka, Fukushima
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Akashi-shi, Takamatsu, Chuo Ku, Chuo-ku Osaka-shi, Gifu, Hamamatsu, Hiroshima, Izumi-shi
2024-11-22
Active, closed
AbbVie
Phase 2
74
Nagoya, Kashiwa-shi, Suita-shi, Kitaadachi-gun, Chuo-Ku
2024-11-08
Active, closed
Merus B.V.
Phase 3
699
Nagoya, Kashiwa, Fukuoka, Hiragi, Natori-shi, Sendai, Ōsaka-sayama, Chuo Ku
2024-09-25
Recruiting
NovoCure GmbH
Phase 3
734
Sakai, Hidaka, Bunkyo, Chuo-ku
2024-07-31
Active, closed
Amgen
Phase 1
120
Nagoya, Kashiwa-shi, Yokohama, Chuo-ku
2024-05-29
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
31
Kashiwa-shi, Sendai, Niigata, Osaka, Osakasayama-shi, Sunto-gun, Chuo-ku, Koto-ku
2024-05-07
Recruiting
Daiichi Sankyo
Phase 1/2
680
Nagoya, Kashiwa, Matsuyama, Ōsaka-sayama, Nagaizumi-cho, Chuo-ku, Koto-ku, Saitama
2024-04-10
Active, closed
AbbVie
Phase 2/3
167
Kashiwa-shi, Kitaadachi-gun, Chuo-ku
2024-04-10
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa
2024-03-12
Active, closed
AbbVie
Phase 1
152
Kashiwa-shi, Kyoto, Chuo-ku
2024-03-08
Active, closed
Pfizer
Phase 1/2
71
Kashiwa, Yokohama, Chuo-ku, Tokyo
2024-02-19
Active, closed
Pfizer
Phase 2
333
Otashi, Sendai, Suita, Chuo-ku, Chiba, Hiroshima, Osaka
2024-01-09
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Nagoya, Chuo-ku, Chūō, Fukuoka
2023-12-29
Active, closed
AbbVie
Phase 2
280
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-ku
2023-11-12
Recruiting
AbbVie
Phase 1
325
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-Ku, Koto-ku
2023-11-09
Active, closed
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
NCT06049212Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
30
Nagoya, Kashiwa, Matsuyama, Yokohama, Hirakata, Nagaizumi-cho,Sunto-gun, Chuo-ku
2023-10-26
Recruiting
Pfizer
Phase 2
340
Yokohama, Osaka, Chuo-ku, Setagaya-ku
2023-08-22
Active, closed
Pfizer
Phase 3
59
Nagoya, Kashiwa, Chuo-ku
2023-08-09
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Nagoya, Kashiwa-shi, Fukuoka, Sendai, Niigata, Sayama, Sunto-gun, Chuo Ku
2023-07-31
Active, closed
AbbVie
Phase 1
135
Kashiwa-shi, Kyoto, Chuo-ku, Koto-ku
2023-06-09
Recruiting
Chugai Pharmaceutical
Phase 1
209
Nagoya, Kashiwa-shi, Yokohama, Hirakata-shi, Osaka, Sakai-shi, Nagaizumi-chō, Chuo-ku
2023-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Nagoya, Kashiwa, Kitaadachi-gun, Nagaizumi-cho,Sunto-gun, Chuo-ku
2023-05-16
Recruiting
National Cancer Center, Japan
Phase 2
32
Kashiwa, Sapporo, Kyoto, Sendai, Chuo-ku, Fukuoka
2023-03-29
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Recruiting
Lantern Pharma Inc.
Phase 2
90
Sapporo, Yokohama, Sendai, Okayama, Chuo-ku
2023-03-01
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Nagoya, Asahikawa, Chuo Ku, Hamamatsu, Shinjuku-Ku, Osaka
2023-01-05
Active, closed
AbbVie
Phase 1
288
Kashiwa-shi, Matsuyama, Sapporo, Kyoto, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2022-12-05
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Chuo Ku
2022-10-26
Active, closed
Genmab
Phase 1
17
Nagoya, Kyoto, Osaka, Chuo-ku, Setagaya-ku
2022-10-04
Active, closed
Eli Lilly and Company
Phase 2
46
Kobe, Chuo-ku, Fukuoka
2022-09-20
Active, closed
Pfizer
Phase 1
6
Nagoya, Kashiwa, Chuo-ku
2022-08-16
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Nagoya, Sapporo, Isehara, Sendai, Sakai, Chuo-ku, Koto, Fukuoka
2022-07-21
Recruiting
Chiome Bioscience Inc.
Phase 1
70
Nagaizumicho, Chuo-Ku
2022-06-27
Active, closed
Genmab
Phase 2
264
Sapporo, Kyoto, Chuo-ku
2022-06-14
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Nagoya, Kashiwa, Yokohama, Sakai, Suita, Chuo-ku, Koto-ku
2022-06-07
Recruiting
Shionogi
Phase 1/2
282
Kashiwa, Suita, Chuo Ku
2022-05-30
Recruiting
National Cancer Center, Japan
Observational
60
Chuo-ku
2022-05-24
Active, closed
Amgen
Phase 1/2
329
Nagoya, Kashiwa-shi, Chuo-ku
2022-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Kashiwa, Yokohama, Nakatogari, Chuo-ku, Koto
2021-12-17
Recruiting
National Cancer Center, Japan
Observational
1,000
Chuo-ku
2021-11-30
Recruiting
AbbVie
Phase 1
694
Nagoya, Kashiwa-shi, Kobe, Hirakata-shi, Sunto-gun, Chuo-ku, Wakayama
2021-11-01
Recruiting
Bayer
Phase 1/2
430
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sakai, Sunto, Chuo-ku
2021-10-25
Active, closed
Novartis Pharmaceuticals
Phase 1
137
Chuo Ku
2021-10-21
Active, closed
AbbVie
Phase 1
520
Nagoya, Kashiwa-shi, Yokohama, Kyoto, Niigata, Chuo-ku, Koto-ku, Wakayama
2021-10-13
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Kurume, Suita, Chuo Ku, Minato-Ku, Shinjuku-Ku, Matsuyama, Nagoya, Niigata
2021-10-11
Active, closed
Pfizer
Phase 3
77
Yufu, Chuo-ku, Koto, Fukuoka
2021-09-29
Active, closed
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
NCT05023551High Grade Glioma, Glioblastoma Multiforme
Sumitomo Pharma America, Inc.
Early Phase 1
39
Sapporo, Kyoto, Chuo Ku
2021-09-08
Active, closed
Pfizer
Phase 3
38,861
Fukuoka, Itoshima, Amagasaki, Yokohama, Osaka, Kawaguchi, Chuo-ku, Hachioji-shi
2021-08-31
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Sapporo, Yokohama, Nankoku, Chuo-ku, Kyoto, Tokyo
2021-08-12
Active, closed
HUYABIO International, LLC.
Phase 3
450
Fukuoka, Matsumoto, Niigata, Okayama, Chuo Ku, Osaka, Nagaizumi-cho, Kōtoku
2021-08-12
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Nagoya, Kashiwa, Sapporo, Kanazawa, Chuo-ku, Wakayama
2021-07-19
Active, closed
Bristol-Myers Squibb
Phase 3
729
Nagoya, Sapporo, Tsu, Kawachi-Nagano, Bunkyō, Chuo-ku, Itabashi-ku, Meguro-ku
2021-07-15
Active, closed
Daiichi Sankyo
Phase 1
246
Matsuyama, Fukuoka, Sapporo, Yokohama, Okayama, Chuo Ku, Iwakuni-shi, Ōsaka-sayama
2021-06-11
Active, closed
Daiichi Sankyo
Phase 2
155
Nagoya, Kashiwa, Sapporo, Chuo Ku, Fukuoka, Kagoshima, Kyoto, Nagasaki
2021-06-03
Recruiting
Calico Life Sciences LLC
Phase 1
248
Chuo-ku, Wakayama
2021-03-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Nagoya, Kashiwa, Osaka, Chuo Ku, Koto Ku
2021-02-24
Active, closed
AbbVie
Phase 1
81
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Chuo-ku
2021-02-23
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
250
Higashiku, Yokohama, Sendai, Chikusa-ku, Shōwaku, Niigata, Kita-ku, Chuo-ku
2021-01-20
Active, closed
Daiichi Sankyo
Phase 1
179
Chuo Ku, Kashiwa-shi, Fukuoka, Kōtoku, Matsuyama, Nakatogari, Saitama
2020-12-22
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Kashiwa-shi, Sendai, Okayama, Hirakata-shi, Osaka, Shizuoka, Chuo-ku, Koto-ku
2020-12-16
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole
Pfizer
Phase 2
320
Nagoya, Kashiwa, Yokohama, Chuo-ku
2020-11-16
Active, closed
Eli Lilly and Company
Phase 1
200
Kashiwa, Yokohama, Suita-shi, Nakatogari, Chuo-ku
2020-10-01
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Nagoya, Kashiwa-shi, Kawasaki, Osaka, Chuo-ku, Koto-ku
2020-09-15
Recruiting
Eisai Inc.
Phase 1/2
182
Chuo-ku, Koto-ku
2020-08-06
Active, closed
Celgene
Phase 2
276
Sapporo, Chuo-ku, Minato-ku, Fukuoka
2020-07-14
Active, closed
Eli Lilly and Company
Phase 1
71
Chuo-ku
2020-06-11
Active, closed
Eli Lilly and Company
Phase 3
261
Kashiwa, Sapporo, Kanazawa, Yokohama, Osaka Sayama-shi, Nakatogari, Chuo-ku, Koto
2020-02-17
Active, closed
Institut de Recherches Internationales Servier
Phase 3
331
Nagoya, Toyoake, Minami-Ku, Bunkyō-Ku, Chuo Ku, Kumamoto, Kyoto, Okayama
2020-01-05
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Akashi, Chuo-ku
2019-12-10
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Kobe, Higashi Ibaraki-gun, Okayama, Chuo-ku
2019-09-06
Active, closed
Eisai Co., Ltd.
Phase 1/2
125
Nagoya, Kashiwa, Matsuya, Kurume, Akashi, Yokohama, Sendai, Chuo Ku
2019-09-05
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
Sapporo, Chuo-ku, Hiroshima, Kyoto
2019-06-13
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Sapporo, Nagaizumi-Cho, Chuo-ku, Niigata, Osaka
2019-06-04
Active, closed
Rakuten Medical, Inc.
Phase 3
135
Nagoya, Sapporo, Okayama, Chuo-ku
2019-05-09
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Chuo Ku
2019-05-07
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Nagoya, Kashiwa, Sapporo, Yokohama, Kashihara, Bunkyo-ku, Chuo-ku, Koto-ku
2019-03-15
Active, closed
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
NCT03833700Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
DrugE7386
Eisai Co., Ltd.
Phase 1
70
Nagoya, Kashiwa, Sapporo, Sendai, Nagaizumi-cho, Chuo Ku, Fukuoka, Osaka
2019-03-05
Active, closed
AbbVie
Phase 1
364
Kashiwa-shi, Akashi-shi, Chuo-ku
2019-02-21
Recruiting
Celgene
Phase 2/3
1,541
Chiba, Sapporo, Tennoji-Ku, Shimotsuke, Chuo-ku, Minato-ku, Bunkyō City, Fukuoka
2018-07-19
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Kashiwa, Chuo Ku
2018-01-26
Active, closed
Amgen
Phase 1
269
Kashiwa-shi, Chuo-ku, Wakayama
2017-12-26
Active, closed
Eisai Co., Ltd.
Phase 1
140
Kashiwa, Sapporo, Nishinomiya, Yokohama, Hidaka, Bunkyo-ku, Chuo-ku, Koto-ku
2017-08-18
Active, closed
ModernaTX, Inc.
Phase 1
161
Kashiwa-Shi, Chuo-Ku, Tokyo, Osakasayama-Shi
2017-08-14
Active, closed
Eli Lilly and Company
Phase 1/2
857
Nagoya, Kashiwa, Sapporo, Akashi, Kanazawa, Osaka Sayama-shi, Nagaizumi-cho,Sunto-gun, Chuo-ku
2017-05-02
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Tōon, Sapporo, Yokohama, Osaka, Chuo-ku, Yonago, Kashiwa, Nagoya
2017-03-07
Active, closed
AbbVie
Phase 1
163
Kashiwa-shi, Chuo-ku
2017-02-22
Active, closed
Eli Lilly and Company
Phase 1
223
Chuo-Ku
2016-11-21
Active, closed
Bayer
Phase 1/2
154
Yokohama, Chuo-ku, Fukuoka
2015-12-16
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Sapporo, Sendai, Chuo Ku, Fukuoka, Kyoto
2015-11-02
Active, closed
AbbVie
Phase 1
237
Kashiwa-shi, Chuo-ku
2014-01-15
Rows per page Showing 1–147 of 147
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/chuo-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 147 of those studies with a site in Chuo Ku.

How many clinical trials are recruiting in Chuo Ku?

77 of the 147 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 3 have not yet opened recruitment, 67 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chuo Ku), 147 studies
PhaseStudiesRecruitingShare
Phase 1441829.9%
Phase 2341723.1%
Phase 3291519.7%
Phase 1/2281919%
Phase 2/3533.4%
Observational322%
Not applicable221.4%
Early Phase 1100.7%
Phase 4110.7%

Most active sponsors

Lead sponsors with the most studies (Chuo Ku)
Lead sponsorStudiesRecruiting
AbbVie2411
Novartis Pharmaceuticals159
Pfizer157
Eli Lilly and Company90
Amgen83
Bristol-Myers Squibb86
Astellas Pharma Global Development, Inc.65
Bayer53
Daiichi Sankyo52
Merck Sharp & Dohme LLC53
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.